# OnCo record nct06943872 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06943872/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06943872", "NCT06943872" ;
  schema:name "A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)"@en ;
  schema:alternateName "CELESTIAL-RRCLL"@en ;
  schema:description "A phase 3 trial of Sonrotoclax, Obinutuzumab, Rituximab and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06943872/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06943872> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-06-11" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cll-relapsed/> ;
  onco:technologies <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/sonrotoclax/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/venetoclax/> ;
  onco:companies <https://onco.cc/companies/beone/> .